Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villejuif – page 62

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
929
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

929 trials in Villejuif

Open in trial search

Biliary neoplasm+1

Not recruiting

Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Neoplasm

Not recruiting

Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Eli Lilly & Co.

Anal cancer recurrent

Not recruiting

Study of Retifanlimab, Carboplatin, and Paclitaxel for Patients with Inoperable or Metastatic Anal Canal Squamous Cell Carcinoma Not Treated with Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Incyte Corp.

Neoplasm malignant+2

Not recruiting

Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tyra-300-B01
  • Sponsor:Tyra Biosciences Inc.

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Radiation skin injury

Not recruiting

Study on GR1014 Gel to Prevent Skin Damage from Radiation in Breast Cancer Patients After Lumpectomy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amifostine Thiol
  • Sponsor:Graegis Pharmaceuticals Limited

Neoplasm malignant

Not recruiting

A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gen1047
  • Sponsor:Genmab A/S

Non-Hodgkin's lymphoma+13

Not recruiting

Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tazemetostat
  • Sponsor:Epizyme Inc.

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.